


## PHARMACEUTICAL 2018

## Oncternal Therapeutics Inc. Rank 144 of 342





## PHARMACEUTICAL 2018

## Oncternal Therapeutics Inc. Rank 144 of 342

The relative strengths and weaknesses of Oncternal Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Oncternal Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 85% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	46,077
Cost of Goods Sold	0
Intangible Assets	108
Liabilities, Current	7,975
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	216
Other Revenues	0
Property and Equipment	51
Research and Development	21,467
Selling, General and Administrative Expense	9,188

Output Variable	Value in 1000 USD
Assets	46,236
Liabilities	7,975
Expenses	30,655
Revenues	0
Stockholders Equity	38,261
Net Income	-30,439
Comprehensive Net Income	-30,439
Economic Capital Ratio	130%

